IA
CRDL

Integrity Alliance’s Cardiol Therapeutics CRDL Stock Holding History

Integrity Alliance’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Sell
388,492
-76,533
-16% -$96.9K 0.01% 572
2026
Q1 		$630K Buy
465,025
+30,000
+7% +$30.8K 0.02% 392
2025
Q4 		$416K Buy
+435,025
New +$456K 0.02% 513

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Integrity Alliance's CRDL Position: Q2 2026 in Review

Integrity Alliance reduced its Cardiol Therapeutics (CRDL) stake by 16% in Q2 2026, selling an estimated $96.9K and leaving 388,492 shares worth $412K. The position accounts for 0.01% of the portfolio, ranked #572.

Integrity Alliance first reported a position in CRDL in Q4 2025 and has held it in 3 quarters since. The position peaked at $630K in Q1 2026. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Integrity Alliance held 388,492 shares of Cardiol Therapeutics worth $412K as of Q2 2026.
  • Integrity Alliance sold 76,533 Cardiol Therapeutics shares in Q2 2026, an estimated $96.9K.
  • Cardiol Therapeutics made up 0.01% of Integrity Alliance's portfolio in Q2 2026, its #572 holding.
  • Integrity Alliance first reported a position in Cardiol Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Integrity Alliance's Cardiol Therapeutics position peaked at $630K in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Integrity Alliance's 13F filing for Q2 2026, filed 31 Jul 2026.